The right go-to-market GTM strategy has wide-ranging impacts on commercial success, allowing for the optimal balance of profit potential and commercial control with financial commitment and implementation risk. However, the inherent complexity of cell-based therapies brings together unique clinical, training, manufacturing,
logistical and market access challenges that need to be considered when choosing a GTM strategy.
This paper explores market trends and key considerations unique to cellular immunotherapies, and how choosing the right GTM strategy can impact the trajectory of their commercial success.
Download the white paper now.
